These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

304 related articles for article (PubMed ID: 26785065)

  • 21. Clinical practice guidelines for the prevention, diagnosis, evaluation and treatment of mineral and bone disorders in chronic kidney disease (CKD-MBD) in adults.
    Bellorin-Font E; Ambrosoni P; Carlini RG; Carvalho AB; Correa-Rotter R; Cueto-Manzano A; Jara A; Jorgetti V; Negri AL; Olaizola I; Salusky I; Slatopolsky E; Weisinger JR; ;
    Nefrologia; 2013; 33 Suppl 1():1-28. PubMed ID: 23629678
    [TBL] [Abstract][Full Text] [Related]  

  • 22. An introduction to CKD-MBD research: restart for the future.
    Fukagawa M; Inaba M; Yokoyama K; Shigematsu T; Ando R; Miyamoto KI;
    Clin Exp Nephrol; 2017 Mar; 21(Suppl 1):1-3. PubMed ID: 28083765
    [No Abstract]   [Full Text] [Related]  

  • 23. Management of chronic kidney disease: what is the evidence?
    Brosnahan G; Fraer M
    South Med J; 2010 Mar; 103(3):222-30. PubMed ID: 20134375
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Parathyroid function in chronic kidney disease: role of FGF23-Klotho axis.
    Koizumi M; Komaba H; Fukagawa M
    Contrib Nephrol; 2013; 180():110-23. PubMed ID: 23652554
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Managing bone mineral disorders in CKD: an overview of current therapies.
    Delaney M
    J Ren Care; 2009 Mar; 35 Suppl 1():107-10. PubMed ID: 19222741
    [No Abstract]   [Full Text] [Related]  

  • 26. Hyperparathyroidism in chronic kidney disease patients: an update on current pharmacotherapy.
    Fukagawa M; Komaba H; Kakuta T
    Expert Opin Pharmacother; 2013 May; 14(7):863-71. PubMed ID: 23521343
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Role of cinacalcet in management of mineral bone disorder in chronic kidney disease (control of calcium, phosphorus and parathyroid hormone).
    Tahara H
    Ther Apher Dial; 2008 Oct; 12 Suppl 1():S27-33. PubMed ID: 19032524
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Evidence-Based Interventions for Prevention of Bone Density Loss after Kidney Transplant.
    Carpenter PC; Koo LW
    Nephrol Nurs J; 2015; 42(3):209-19; quiz 220. PubMed ID: 26207283
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Survey of attitudes of physicians toward the current evaluation and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD).
    Souqiyyeh MZ; Shaheen FA
    Saudi J Kidney Dis Transpl; 2010 Jan; 21(1):93-101. PubMed ID: 20061700
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Improved patient outcomes in chronic kidney disease: optimizing vitamin D therapy.
    Gesek FA; Desmond JS
    Nephrol Nurs J; 2008; 35(2 Suppl):5S-22S; quiz 23S. PubMed ID: 18505229
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Recent Changes in Chronic Kidney Disease-Mineral and Bone Disorders and Associated Fractures After Kidney Transplantation.
    Perrin P; Kiener C; Javier RM; Braun L; Cognard N; Gautier-Vargas G; Heibel F; Muller C; Olagne J; Moulin B; Ohlmann S
    Transplantation; 2017 Aug; 101(8):1897-1905. PubMed ID: 27547867
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Parathyroid and bone. Management of parathyroid function and evaluation of bone metabolism in hemodialysis patients].
    Goto S; Fukagawa M
    Clin Calcium; 2007 Dec; 17(12):1830-4. PubMed ID: 18057657
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Hyperparathyroidism and bone disease after renal transplantation.
    Pavlović D; Orlić L
    Acta Med Croatica; 2002; 56(2):41-3. PubMed ID: 12596622
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Pharmaceutical therapy of bone metabolism disorders in chronic kidney disease mineral bone disorder (CKD-MBD) with special respect to antiresorptive substances].
    Lehmann G; Wolf G
    Z Rheumatol; 2014 May; 73(4):329-34. PubMed ID: 24811357
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Metabolic bone disease after renal transplantation.
    Haffner D; Schüler U
    Curr Opin Pediatr; 2014 Apr; 26(2):198-206. PubMed ID: 24535492
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Physiopathology and therapy of renal osteodystrophy and secondary hyperparathyroidism].
    Fukagawa M
    Nihon Naika Gakkai Zasshi; 1999 Jul; 88(7):1245-50. PubMed ID: 10465972
    [No Abstract]   [Full Text] [Related]  

  • 37. Mineral metabolism disturbances in patients with chronic kidney disease.
    Kestenbaum B; Belozeroff V
    Eur J Clin Invest; 2007 Aug; 37(8):607-22. PubMed ID: 17635571
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Focus on vitamin D therapy in chronic kidney disease.
    Tentori F
    J Nephrol; 2007; 20(5):511-4. PubMed ID: 17918134
    [No Abstract]   [Full Text] [Related]  

  • 39. [Treatment of mineral bone disorder with pharmaceuticals which influence the calcium phosphor turnover].
    Vestergaard P; Eiken PA
    Ugeskr Laeger; 2012 Nov; 174(47):2931-4. PubMed ID: 23171790
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Update on the new Kidney Disease: Improving Global Outcomes (KDIGO) guidelines for mineral and bone disorders (MBD)--a focus on medications.
    Raymond CB; Wazny LD; Sood AR
    CANNT J; 2010; 20(1):42-6; quiz 47-8. PubMed ID: 20426360
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.